SCHWARZENBRUCK, 30 November 2017 – IBA (Ion Beam Applications S.A.), the world’s leading provider of proton therapy solutions and radiation therapy integrated quality assurance (QA) for the treatment of cancer, announces the acceptance and beam model validation of the first Varian Halcyon™ machine in Europe to go clinical, at the hospital UZ Leuven in Belgium, using IBA Dosimetry’s Blue Phantom water phantom system.

Professor Tom Depuydt, Head of Physics at UZ Leuven, Belgium, said: “We are very happy to announce that we were able to deliver the first treatment fraction with the Varian Halcyon™ system on October 2nd, within just 14 days of the machine’s installation. This was made possible by the fruitful collaboration of our physics team and IBA Dosimetry, and use of the Blue Phantom system to ensure fast and reliable acceptance of our new machine.”

The Blue Phantom system enables fast and seamless beam scanning workflows that are ideal for verification and annual QA of the Varian Halcyon™. Next to the compact design, the phantoms conveniently accessible micro-leveling frame enables fast and precise system setup.

Christian Neumeier, Marketing Specialist for Relative and Absolute Dosimetry at IBA Dosimetry, said: “We are very proud that we have reached this important milestone together with UZ Leuven, the first hospital in Europe to go clinical with a Varian Halcyon™ machine by using our internationally known Blue Phantom system. This milestone is testimony to the system’s unique technology and the benefits of its use in Halcyon™ verification and annual QA.”  

About IBA Dosimetry

IBA Dosimetry GmbH innovates radiation therapy, proton therapy and diagnostic imaging through integrated Quality Assurance solutions that are efficient, intuitive and that provide peace of mind for healthcare professionals and patients around the world. The myQA® Global QA Platform is the backbone for Integrated Quality Assurance solutions. IBA Dosimetry has more than 220 international employees in four offices in Germany, France, China and USA.

Find more information at: www.iba-dosimetry.com

About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com  

About UZ Leuven

There are 1,955 beds in the University Hospitals Leuven, making it the largest university hospital in Belgium. Every day, more than 9,000 enthusiastic employees do their utmost to provide diverse and specialist patient care and work continuously on improving and updating that care. The University Hospitals Leuven’s strength lies in combining top quality patient care, excellent innovative scientific research and high-standing academic training. It was also the first Belgian hospital to acquire the international JCI label for safe and quality care. More information can be found at: www.uzleuven.be